Anaphylaxis as an adverse event following immunisation in the UK and Ireland

Archives of Disease in Childhood

Volumn 97, Issue 6, 2012, Pages 487-490

  Erlewyn Lajeunesse, Michel ^a   Hunt, Linda P ^b   Heath, Paul T ^c   Finn, Adam ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; HEPATITIS A VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; SALBUTAMOL; TYPHOID VACCINE; WART VIRUS VACCINE;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CAPILLARY FLOW; CHILD; CLINICAL ARTICLE; CONSCIOUSNESS; COUGHING; DIARRHEA; DRUG ERUPTION; DYSPNEA; ERYTHEMA; FLUID THERAPY; HEALTH PROGRAM; HIGH RISK PATIENT; HOARSENESS; HUMAN; HYPOTENSION; IMMUNIZATION; INCIDENCE; INJECTION SITE REACTION; IRELAND; MEASLES; MENINGOCOCCEMIA; NAUSEA; PEDIATRICIAN; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RESPIRATORY DISTRESS; SHOCK; SIDE EFFECT; SNEEZING; STRIDOR; SYMPTOM; TACHYCARDIA; THROAT TIGHTNESS; TYPHOID FEVER; UNITED KINGDOM; VIRUS INFECTION; VOMITING; WART VIRUS; WHEEZING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; CHILD; CHILD, PRESCHOOL; GREAT BRITAIN; HUMANS; IMMUNIZATION; INCIDENCE; INFANT; IRELAND; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; VACCINES;

EID: 84861482070     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2011-301163     Document Type: Article

References (23)

1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7. (Pubitemid 43190153)
2. Madaan A, Maddox DE. Vaccine allergy: diagnosis and management. Immunol Allergy Clin North Am 2003;23:555-88. (Pubitemid 38030159)
3. Pool V, Braun MM, Kelso JM, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics 2002;110:e71.
4. Lynn R, Ross E. The British Paediatric Surveillance Unit: the first 20 years. Arch Dis Child 2007;92:744-5. (Pubitemid 47372521)
5. Rüggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5675-84. (Pubitemid 47049764)
6. Erlewyn-Lajeunesse M, Bonhoeffer J, Ruggeberg JU, et al. Anaphylaxis as an adverse event following immunisation. J Clin Pathol 2007;60:737-9. (Pubitemid 47056900)
7. Buettcher M, Heininger U, Braun M, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2007;25:5875-81. (Pubitemid 47049773)
8. Peng MM, Jick H. A population-based study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch Intern Med 2004;164:317-19. (Pubitemid 38176473)
9. Llewellyn M. Anaphylaxis following paediatric immunization. Ir Med J 2006;99:125.
10. Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003;112:815-20. (Pubitemid 37248689)
11. Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003;52:1-24.
12. Department of Health. Vaccine safety and the mangement of adverse events following immunisation. Immunisation Against Infectious Disease. Department of Health 2006:53-64.
13. Sonnenberg P, Crowcroft NS, White JM, et al. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales. Arch Dis Child 2007;92:786-9. (Pubitemid 47372532)
14. Erlewyn-Lajeunesse M, Manek R, Lingam R, et al. Anaphylaxis following single component measles and rubella immunisation. Arch Dis Child 2008;93:974-5.
15. Brotherton JM, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008;179:525-33.
16. Kang LW, Crawford N, Tang ML, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 2008;337:a2642.
17. Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumpsrubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000;19:1127-34. (Pubitemid 32003354)
18. Nakayama T, Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 2007;25:570-6. (Pubitemid 44856088)
19. Salisbury D. Immunisation Against Infectious Disease. Fourth edition. London: TSO 2006;25:570-6.
20. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, et al. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009;339:b3680.
21. Erlewyn-Lajeunesse M, Dymond S, Slade I, et al. Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK. Drug Saf 2010;33:57-64.
22. Gold M, Goodwin H, Botham S, et al. Re-vaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. Arch Dis Child 2000;83:128-31. (Pubitemid 30670421)
23. Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008;122:e771-7.